CRISPR Medicine

Bayer

Main (gene editing) focus: Next-generation in vivo delivered gene-editing therapies

Company stage: Commercial

Diseases (gene editing): Genetic diseases of the liver, haemophilia, ophthalmology and autoimmune diseases

Genome editing tool: CRISPR-Cas9, Cas14 and Casɸ

Funding stage: Public (XETRA:BAYN.DE)

Location: Berlin, Germany

Website: https://www.bayer.com/en/pharma/development-pipeline

Pipeline: https://www.bayer.com/en/pharmaceuticals

Gene editing partnerships: Mammoth Biosciences, Casebia Therapeutics


Bayer is a big pharma company with worldwide operations. The company is engaged in the gene-editing field by its joint venture firm, Casebia Therapeutics, which it launched together with CRISPR Therapeutics. The company also announced a collaboration with Mammoth Biosciences, where the two companies will utilise Mammoth's ultra-small Cas enzymes, Cas14 and Casɸ, for in vivo gene editing of multiple disease targets.

See the full view ...